Halozyme Sees Zero to Minimal Royalty Revenue Impact From Medicare Drug Pricing Rule Through at Least 2035
Bitget2026/11/06 15:05- Halozyme Therapeutics reaffirmed expectations for zero to minimal royalty revenue impact through at least 2035 under Medicare drug price negotiations.
- The outlook reflects its analysis of CMS’s final rule issued Nov. 5, 2026, for the 2029 program and applicable statutory provisions.
- Orphan drug protections and the effects of biosimilar entry on program eligibility support the forecast.
- No impact is projected on its ability to secure new ENHANZE partnerships, which remain driven by patient treatment experience and competitive differentiation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CryptoQuant analyst says the altcoin market cap has shrunk by about $20 billion
![Fu Peng: Pay attention to the potential shift in copper from stockpiling to bottleneck logic [Fu Peng Commentary]](https://img.bgstatic.com/external-content/5bba8cd4c8254af78616bb3a2e614b63.jpg?w=420&h=236&f=webp)
Ripple's Dubai Event Presence Gets High-Profile Boost From Emirates Chairman
Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"
Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.
Crypto prices
More
